COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
A study released by the Centers for Disease Control and Prevention estimates 299,028 more deaths than expected occurred in the United States between Jan. 26 and Oct. 3, with 66% attributed to COVID-19.
Other Events This Week Include HHS Webinars on COVID-19 Data Reporting and AHA Leadership Rounds with AHA Chair Dr. Estes
A national training collaborative that aims to provide every person working in a U.S. healthcare facility the foundation for infection control to protect the nation from infectious disease threats, such as COVID-19.
The Food and Drug Administration Oct. 15 removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health emergency by outsourcing facilities and state-licensed pharmacies or federal facilities not registered as outsourcing facilities.
The Food and Drug Administration Oct. 15 said it reissued its emergency use authorization for certain, Chinese-manufactured filtering face-piece respirators that lack National Institute for Occupational Safety and Health approval.
The Centers for Medicare & Medicaid Services Oct. 15 said it will incentivize labs to deliver quicker results to patients undergoing COVID-19 diagnostic testing.
The Food and Drug Administration Oct. 13 issued and immediately implemented enforcement policy for modifications to FDA-cleared molecular influenza and RSV tests during the COVID-19 public health emergency to expand access to certain FDA-cleared molecular tests for detecting and identifying flu鈥
Ask Your Representatives to Sign 鈥楧ear Colleague鈥 Letter Urging HHS to Reinstate June COVID-19 Provider Relief Fund Reporting Requirements
Please contact your representatives today and ask them sign on to a 鈥淒ear Colleague鈥 letter to the Department of Health and Human Services (HHS) urging it鈥
The Centers for Disease Control and Prevention Oct. 22 at 2 p.m. ET will host a Clinician Outreach and Communication Activity webinar on improving clinicians鈥 understanding the relationship between COVID-19 and the concerns of people who use drugs or who have a substance use disorder.
The Food and Drug Administration Oct. 12 issued an emergency use authorization for Abbott Laboratories鈥 AdviseDx SARS-CoV-2 IgM (Immunoglobulin M) lab-based serology test.